Definitive clinical or radiologic evidence of metastatic disease; required imaging studies must have been performed within 90 days prior to randomization
Clinical or radiographic evidence of metastatic disease; metastatic workup is not required, but is recommended for patients with clinical stage III disease; Note: isolated ipsilateral supraclavicular node involvement is permitted
Definitive clinical or radiologic evidence of metastatic disease
Definitive clinical or radiologic evidence of metastatic disease
Definitive clinical or radiologic evidence of metastatic disease; no nodal involvement or evidence of metastatic disease allowed as defined by screening of the pelvis
Definitive evidence of metastatic meningioma
Known definitive clinical or radiologic evidence of metastatic disease
Patients with evidence of metastatic disease involvement in viscera or bone
Patients with evidence of myelodysplasia
Evidence or high suspicion of metastatic disease at enrollment
Definitive clinical or radiologic evidence of metastatic disease.
No evidence of extrahepatic metastatic disease
Histologic evidence of DDLS at any time prior to randomization AND current evidence of DDLS requiring treatment
Definitive clinical or radiologic evidence of metastatic disease, as documented by the treating institution
Pathologically proven, radiologic or clinical evidence of distant metastatic disease (this includes all disease below the clavicles, as well as disease metastatic to the bone, brain, or in the spinal canal)
Patient has evidence of metastatic disease
Evidence of metastatic disease
TREATMENT WITH SJCAR19: Evidence of active, uncontrolled neurologic disease
Has evidence of metastatic disease at time of diagnosis.
Evidence of metastatic disease
No evidence of metastatic disease as determined by imaging procedures.
Documented evidence of active acromegaly
Unequivocal evidence of metastatic disease defined by computerized tomography (CT) (includes resectable metastases)
Evidence of metastatic disease.
Clinically no evidence of local, regional, or metastatic disease at the time of study entry
Clinical or radiologic evidence of local or regional recurrence of disease or metastatic disease prior to or at the time of study entry
Clinically node negative, no evidence of metastatic disease
Evidence of metastatic disease that is extensive enough to preclude consideration of subsequent definitive surgery for the primary tumor
No evidence of hydronephrosis
Evidence of disease by standard morphologic or by minimal residual disease (MRD) criteria
Evidence of ischemic heart disease as determined by study cardiologist
Evidence of metastatic disease
Definitive clinical or radiologic evidence of metastatic disease; imaging must have been performed no greater than 30 days prior to initiation of chemotherapy
Evidence of hemachromatosis.
Evidence of metastatic disease on imaging studies performed at the discretion of their physician
Evidence of metastatic disease
No evidence of metastatic disease
Any evidence of metastatic disease
M0 stage based on no evidence of metastatic disease by CT imaging.
Clinical evidence or known history of cardiopulmonary disease
Evidence of metastatic disease
Patients with clinical evidence of metastatic disease.
Evidence of ischemic heart disease as determined by study cardiologist
Prior evidence of 1p/19q co-deletion
Patients with evidence of extraneural disease
Patients with evidence of metastatic disease involvement in viscera or bone
Definitive clinical or radiologic evidence of metastatic disease
Patients must have evidence of metastatic disease (non measurable disease is eligible)
Definitive clinical or radiologic evidence of metastatic disease or adenopathy below the clavicles
Definitive clinical or radiologic evidence of metastatic disease; (chest imaging [mandatory for all patients] and other imaging [if required] must have been performed within 90 days prior to randomization)
Patients with evidence of metastatic disease outside of the pelvis
Evidence of metastatic disease outside of the abdomen
Evidence of metastatic disease outside of the abdomen
Current or previous evidence of muscle invasive (muscularis propria) or metastatic disease presented at the screening visit. Examples that increase the risk of metastatic disease are (but not limited to):
Patient with documented evidence of metastatic disease
Clinical or radiologic evidence of local or regional recurrence of disease or metastatic disease prior to or at the time of study entry
No prior or present evidence of metastatic disease;
Definitive clinical or radiologic evidence of progressive disease
Clinical or radiographic evidence of metastatic disease; metastatic workup is not required\r\n* Note: isolated ipsilateral supraclavicular node involvement is permitted
Evidence of extrauterine spread of disease on imaging or during surgical evaluation
Definite evidence of metastatic disease
There is no evidence of disease relapse at the time of screening, and minimal residual disease (MRD) is acceptable
Evidence of metastatic disease
Definitive clinical or radiologic evidence of metastatic disease.
No evidence of disease at the time of registration, including no clinical concern for disease recurrence based on each of the following:\r\n* No evidence of disease by history and physical exam\r\n* Cancer antigen (CA)125 within normal limits\r\n* Computed tomography (CT) abdomen/pelvis demonstrating no radiological evidence of disease performed after completion of chemotherapy =< 28 days before entering study
Evidence of metastatic disease
Evidence of metastatic disease (stage M1)
No evidence of disease by standard morphology; minimal residual disease or molecular evidence of disease will not exclude
Currently have no clinical evidence of disease
No evidence of extranodal metastatic disease
Definitive clinical or radiologic evidence of metastatic disease; indeterminant lung nodules less than 8 mm are acceptable
Resectable primary tumor with no evidence of metastatic disease by imaging. Imaging must be performed within 45 days of Day 1 of study.
Evidence of extrauterine spread of disease on imaging or during surgical evaluation
Definitive clinical or radiologic evidence of metastatic disease; pN3 disease is not allowed (positive common iliac node)
Patients with only locally or regionally confined disease without evidence of metastatic disease
No evidence of metastatic disease
Has a prior history or current evidence of intracranial (CNS) metastatic RCC, except for ?3 lesions treated by CyberKnife or excisional surgery, clinically stable for at least 4 weeks, and without evidence of recurrence on MRI imaging at screening.
Evidence of nephrectomy
Clinical or radiologic evidence of distant metastatic disease other than small volume (<1.5 cm) nodes, this should be tested within 12 months from enrollment;
Participants with evidence of non-hepatic metastatic disease
Subjects who have clinical evidence of carcinoid-induced heart disease
No evidence of known metastatic disease (M0 or Mx allowed)
Evidence of encephalopathy within last 3 months
Completely resected hepatic metastases without current evidence of other metastatic disease
Patients with known primary or metastatic CNS disease (cohort B), are not eligible if they have a mini mental state exam score < 15 or evidence of leptomeningeal disease
Evidence of metastatic disease on imaging studies
Definitive clinical or radiologic evidence of metastatic disease; if applicable
Definitive evidence of multifocal disease
No evidence of disease
Cancer survivor, with no evidence of active disease
Clinical evidence of metastatic disease
Have no current evidence of disease
Survivors must not have evidence of recurrent or metastatic disease
Evidence of complete response at three months post-treatment; maintenance therapy is permitted as long as there is no evidence of disease
There is evidence of the disease at the time of entry into the trial
Patients seen in the SCC with a diagnosis of cancer with or without evidence of metastatic disease
No known evidence of disease
Have no evidence of recurrence or metastatic disease
Patients who currently have no evidence of disease
Evidence of or treatment for metastatic disease
Evidence of relapsed disease
Patients must be without evidence of M0
Evidence of malignancy within 6 months of study enrollment; this is defined as clear morphologic, radiologic or molecular evidence of disease; mixed chimerism is allowed at the discretion of the clinician
No evidence of residual disease on scan
No evidence of disease metastatic to bone marrow.
Clinical evidence of metastatic (T4b, any N; any T, N2-3; M1) disease
Patients must be without evidence of residual disease as assessed by their treatment team
No evidence of disease
Patients must have evidence of disease either through elevation of tumor markers or radiologic evidence of disease
No evidence of peritoneal disease on preoperative imaging
Patients with a history of CRC without clear evidence of metastatic disease who have completed their acute cancer-specific treatment
No evidence of metastatic disease
Has no evidence of disease
Serum lipase =< ULN at baseline; patients with glucose intolerance should be on a stable regimen and be monitored
Serum lipase =< 1.5 x ULN
Serum lipase =< 1.5 ULN
Lipase: 1.5 x ULN. Subjects with lipase >1.5 x ULN may enrol if there are neither clinical or radiographic signs of pancreatitis
Serum pancreatic lipase < 1.5 x ULN
EXCLUSION - INFUSION: Lipase > 70 U/ml
Serum lipase =< ULN
Lipase =< 1 x ULN.
Lipase =< 1.5 X institutional ULN
Serum lipase > 1.5 x ULN
Lipase =< 1.5 x ULN
Serum lipase =< ULN
Lipase =< 3 x ULN
Lipase =< ULN
Lipase < 2 ULN
Serum lipase =< ULN
CAPMATINIB INCLUSION CRITERIA: Serum lipase =< ULN
Serum lipase =< ULN
For patients being screened for Group 2: Serum lipase > ULN
Serum lipase =< ULN
Serum lipase =< 2 x ULN
Serum lipase =< ULN
Serum lipase > ULN
Serum lipase =< ULN
Lipase < ULN
Lipase =< 1.5 x the ULN
Within 14 days prior to registration: Serum lipase =< 1.5 x institution’s ULN
Lipase > 1.5 ULN; participants with lipase > 1.5 ULN may enroll if there are neither clinical nor radiographic signs of a pancreatitis
Lipase < 1.5 times the ULN
Fasting serum lipase =< institutional ULN
Lipase =< 1.5 x ULN
Serum lipase =< ULN
Lipase =< 1.5 x the ULN
Serum lipase =< ULN
Lipase ? 1.5 x ULN
Lipase =< 1.5 x the ULN
Lipase less than or equal to 2 x ULN
Lipase =< 1.5 x the ULN
Serum lipase =< ULN
Lipase =< 1.5 x the ULN
PART B: Serum lipase =< 1.5 X ULN
Serum lipase =< ULN
Obtained =< 7 days prior to registration: Serum lipase =< 1.5 x ULN
Serum lipase ? 2 x ULN
Serum lipase =< 1.5 x ULN
Lipase levels < 1.5 X ULN
Serum lipase =< ULN
Lipase =< 1.5 x the ULN
Lipase</=1.5 times the ULN
Lipase =< 1.5 x ULN
Serum lipase =< 1 x ULN
Lipase =< 1.5 x ULN
History of lipase > ULN
Serum lipase =< ULN
Lipase =< 1.5 x the ULN
>= grade 2 lipase increased (> 1.5 x ULN)
Lipase =< 1.5 x ULN
Serum lipase =< ULN
Lipase =< 1.5 x the ULN
Lipase =< 1.5 ULN
Serum lipase =< 1.5 x ULN
Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis, within 14 days before the first dose of cabozantinib
Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis within 7 days before the first dose of cabozantinib
Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis
Obtained within 28 days prior to the first dose of cabozantinib: lipase =< 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis.
Lipase =< 2.0 x ULN and no radiologic or clinical evidence of pancreatitis
Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis
Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis
Within 4 days prior to the first dose of cabozantinib: Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis
Lipase < 2.0 x ULN; no radiologic or clinical evidence of pancreatitis
Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis
Within 7 days before the first dose of cabozantinib: Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis
Lipase < 2.0 x ULN; no radiologic/clinical evidence of pancreatitis
Lipase < 2 X the upper limit of normal (ULN) and no radiologic or clinical evidence of pancreatitis
Lipase =< 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis
Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis
Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis
Lipase and amylase =< 2.0 x ULN and no radiologic or clinical evidence of pancreatitis
Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis
Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis
Amylase and lipase =< 1.5 x ULN without any symptoms of pancreatitis
Patients must have amylase or lipase within =< 1.5 x IULN without symptoms of pancreatitis at registration, within 28 days prior to registration
Amylase/lipase =< 1.5 x institutional ULN (without symptoms of pancreatitis)
Asymptomatic serum amylase =< grade 2 and asymptomatic serum lipase =< grade 2; patients with grade 1 or grade 2 serum amylase or lipase at the beginning of the study must be confirmed to have no signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.), at the screening visit
History of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease.
Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease
Note: in the absence of clinical symptoms of pancreatitis, elevations of amylase or lipase are not contraindications to therapy on this trial
History of pancreatitis or history of increased amylase or lipase that was due to pancreatitis
CERITINIB EXCLUSION CRITERIA: History of pancreatitis, or history of increased amylase or lipase that was due to pancreatic disease
Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease
Lipase <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis.
Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease
Serum amylase or serum lipase CTCAE grade ? 1 with signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g. elevated P-amylase, abnormal imaging findings of pancreas, etc)
Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease.
History of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease
History of pancreatitis, or amylase > ULN
Patients with a prior or current history of a second malignancy, impaired GI function, history of pancreatitis or increased amylase or lipase, known diagnosis of HIV, and clinically significant cardiac disease were excluded.
Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease
Lipase <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis.
Lipase ?1.5×ULN and amylase ?1.5×ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis.
Lipase must be <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of pancreatitis and cholecystitis.
